Method development and validation for simultaneous estimation of telmisartan and amlodipine by RP-HPLC
A novel, precise, accurate, rapid and effective isocratic RP-HPLC method was developed, optimized and validated for the estimation of Telimsartan (TEL) and Amlodipine (AML) in pharmaceutical dosage forms (tablet). The drugs were estimated using Symmetry C18 (250 x 4.6 mm, 5 µm) column. A mobile phase composed of phosphate buffer of pH 6 and acetonitrile in the ratio of 40:60, v/v), at a flow rate of 0.8 ml/min was used for the separation. Detection was carried out at 243 nm. The linearity range obtained was 16-48 µg/ml for TEL and 2-6 µg/ml for AML with retention times (Rt) of 3.209 min and 5.351 min for TEL and AML respectively. The correlation coefficient values were found to be 0.999. Precession studies showed % RSD values less than 2 % for both the drugs in all the selected concentrations. The percentage recoveries of TEL and AML were in the range of 98.01-101.62% and 99.30-101.40% respectively. The assay results of TEL and AML were 99.60% and 99.75% respectively. The method was validated as per the International Conference on Harmonization (ICH) guidelines. The developed validated method was successfully used for the quantitative analysis of commercially available dosage form.
Full Text Attachment